CTRI/2009/091/000183Other3 期
A Phase 3, Multi-Center, Open Label Study To Evaluate The Long-Term Safety Of Monotherapy Sitaxsentan Sodium And Combination Therapy With Sitaxsentan Sodium And Sildenafil Citrate In Subjects With Pulmonary Arterial Hypertension. - Not applicable
试验速览
- 阶段
- 3 期
- 状态
- Other
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Ages Eligible for Study: 16 Years to 80 Years
- •Genders Eligible for Study: Both
- •Accepts Healthy Volunteers: No
- •Previously enrolled in B1321001 for at least 4 weeks.
- •Previously enrolled in B1321003, discontinued from the study.
- •Completed the B1321003 study as planned.
排除标准
- •Treated with an investigational drug (other than sitaxsentan or sildenafil in either B1321001 or B1321003) or device that has not received regulatory approval within the 30 days prior to Baseline/Day 1 or during the study.
研究者
相似试验
未知
3 期
ong-Term Open-Label, Safety Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension PatientsPulmonary Arterial HypertensionJPRN-jRCT2080221333Pfizer Japan Inc.35
已完成
不适用
Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety-I270 Primary pulmonary hypertensionPrimary pulmonary hypertensionI270PER-026-09PFIZER S.A.,
未知
3 期
A Phase 3 Pharmacokinetic Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years with HypertensioPediatric hypertensionJPRN-jRCT2080222846TAKEDA PHARMACEUTICAL COMPANY LTD.6
进行中（未招募）
不适用
Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in RussiaProphylaxis against Neisseria meningitidis serogroups A, C, W, and YEUCTR2014-004617-82-Outside-EU/EEAovartis Vaccines and Diagnostics SR198
已完成
3 期
A Phase 3 Multicenter, Open Label Study to Evaluate the Safety of Daily Oral Dosing of Tafamidis Meglumine (PF-06291826-83) 20 mg or 80 mg [or Tafamidis (PF-06291826-00) 61mg] in Subjects Diagnosed with Transthyretin Cardiomyopathy (ATTR-CM))chronic heart failureNL-OMON53130Pfizer12